Magnum Experiment 28
Asset Allocation
Position | Category/Sector | Target Weight |
---|---|---|
CCEP.L Coca-Cola Europacific Partners plc | Consumer Defensive | 0.90% |
DRUG Bright Minds Biosciences Inc | Healthcare | 0.93% |
FTEL Fitell Corporation Ordinary Shares | Consumer Cyclical | 1.88% |
MNPR Monopar Therapeutics Inc. | Healthcare | 1.33% |
PRU.TO Perseus Mining Limited | Basic Materials | 83.53% |
SEZL Sezzle Inc. Common Stock | Financial Services | 3.90% |
WGS GeneDx Holdings Corp. | Healthcare | 4.94% |
ZIVO ZIVO Bioscience, Inc. | Healthcare | 2.59% |
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Magnum Experiment 28, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced every 3 months.
The earliest data available for this chart is Aug 17, 2023, corresponding to the inception date of SEZL
Returns By Period
YTD | 1M | 6M | 1Y | 5Y* | 10Y* | |
---|---|---|---|---|---|---|
^GSPC S&P 500 | -10.18% | -6.92% | -9.92% | 5.42% | 12.98% | 9.70% |
Magnum Experiment 28 | 28.16% | 4.78% | 22.06% | 129.31% | N/A | N/A |
Portfolio components: | ||||||
CCEP.L Coca-Cola Europacific Partners plc | 17.95% | 6.92% | 18.78% | 39.55% | 18.85% | 13.46% |
DRUG Bright Minds Biosciences Inc | -8.08% | -5.40% | -29.87% | 2,705.93% | N/A | N/A |
FTEL Fitell Corporation Ordinary Shares | -92.68% | -12.21% | -96.50% | -91.78% | N/A | N/A |
MNPR Monopar Therapeutics Inc. | 79.95% | 1.25% | 619.82% | 1,067.85% | -0.21% | N/A |
PRU.TO Perseus Mining Limited | 39.66% | 9.33% | 15.30% | 53.72% | 29.90% | 28.65% |
SEZL Sezzle Inc. Common Stock | 5.08% | 16.81% | 19.24% | 357.53% | N/A | N/A |
WGS GeneDx Holdings Corp. | 24.21% | -2.02% | 58.98% | 897.60% | N/A | N/A |
ZIVO ZIVO Bioscience, Inc. | -25.58% | -10.11% | -20.00% | 100.00% | 95.25% | 47.76% |
Monthly Returns
The table below presents the monthly returns of Magnum Experiment 28, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025 | 7.84% | 9.71% | 1.95% | 6.26% | 28.16% | ||||||||
2024 | -3.06% | 5.29% | 24.91% | 5.12% | 11.85% | 9.76% | 4.95% | 4.63% | 8.27% | 35.44% | -0.15% | -12.61% | 131.19% |
2023 | 10.73% | -15.59% | -1.04% | 15.36% | 1.32% | 8.10% |
Expense Ratio
Magnum Experiment 28 has an expense ratio of 0.00%, meaning no management fees are charged. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 99, Magnum Experiment 28 is among the top 1% of portfolios on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
This table presents a comparison of risk-adjusted performance metrics for positions. Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Martin ratio | |
---|---|---|---|---|---|
CCEP.L Coca-Cola Europacific Partners plc | 1.17 | 1.72 | 1.21 | 3.19 | 6.61 |
DRUG Bright Minds Biosciences Inc | 2.00 | 25.81 | 4.15 | 45.83 | 115.81 |
FTEL Fitell Corporation Ordinary Shares | -0.44 | 0.23 | 1.03 | -0.93 | -1.49 |
MNPR Monopar Therapeutics Inc. | 1.78 | 8.47 | 2.20 | 16.40 | 36.68 |
PRU.TO Perseus Mining Limited | 1.26 | 1.81 | 1.22 | 2.48 | 5.18 |
SEZL Sezzle Inc. Common Stock | 2.43 | 3.58 | 1.45 | 5.66 | 12.35 |
WGS GeneDx Holdings Corp. | 6.41 | 5.81 | 1.67 | 19.71 | 60.76 |
ZIVO ZIVO Bioscience, Inc. | 0.82 | 1.85 | 1.30 | 2.24 | 8.30 |
Dividends
Dividend yield
Magnum Experiment 28 provided a 1.93% dividend yield over the last twelve months.
TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
---|---|---|---|---|---|---|---|---|---|---|
Portfolio | 1.93% | 1.83% | 1.50% | 1.31% | 1.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio components: | ||||||||||
CCEP.L Coca-Cola Europacific Partners plc | 0.03% | 0.03% | 0.03% | 0.04% | 0.03% | 0.02% | 0.03% | 0.03% | 0.03% | 0.02% |
DRUG Bright Minds Biosciences Inc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
FTEL Fitell Corporation Ordinary Shares | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
MNPR Monopar Therapeutics Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
PRU.TO Perseus Mining Limited | 2.31% | 2.19% | 1.80% | 1.57% | 1.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SEZL Sezzle Inc. Common Stock | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
WGS GeneDx Holdings Corp. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ZIVO ZIVO Bioscience, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Magnum Experiment 28. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Magnum Experiment 28 was 21.87%, occurring on Oct 5, 2023. Recovery took 104 trading sessions.
The current Magnum Experiment 28 drawdown is 1.25%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-21.87% | Sep 4, 2023 | 24 | Oct 5, 2023 | 104 | Mar 1, 2024 | 128 |
-18.25% | Jul 17, 2024 | 15 | Aug 6, 2024 | 32 | Sep 19, 2024 | 47 |
-16.16% | Oct 30, 2024 | 53 | Jan 14, 2025 | 25 | Feb 18, 2025 | 78 |
-14.21% | Mar 24, 2025 | 10 | Apr 4, 2025 | 5 | Apr 11, 2025 | 15 |
-9.63% | Feb 19, 2025 | 15 | Mar 11, 2025 | 8 | Mar 21, 2025 | 23 |
Volatility
Volatility Chart
The current Magnum Experiment 28 volatility is 14.72%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Diversification
Asset Correlations Table
CCEP.L | FTEL | ZIVO | DRUG | PRU.TO | MNPR | WGS | SEZL | |
---|---|---|---|---|---|---|---|---|
CCEP.L | 1.00 | 0.01 | 0.01 | 0.04 | 0.01 | 0.05 | -0.08 | 0.03 |
FTEL | 0.01 | 1.00 | 0.08 | -0.07 | 0.01 | 0.03 | 0.03 | 0.11 |
ZIVO | 0.01 | 0.08 | 1.00 | 0.04 | -0.11 | 0.03 | 0.09 | 0.08 |
DRUG | 0.04 | -0.07 | 0.04 | 1.00 | 0.07 | 0.10 | 0.02 | 0.12 |
PRU.TO | 0.01 | 0.01 | -0.11 | 0.07 | 1.00 | 0.02 | 0.08 | 0.16 |
MNPR | 0.05 | 0.03 | 0.03 | 0.10 | 0.02 | 1.00 | 0.18 | 0.17 |
WGS | -0.08 | 0.03 | 0.09 | 0.02 | 0.08 | 0.18 | 1.00 | 0.19 |
SEZL | 0.03 | 0.11 | 0.08 | 0.12 | 0.16 | 0.17 | 0.19 | 1.00 |